• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by AirSculpt Technologies Inc.

    8/12/24 11:51:56 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care
    Get the next $AIRS alert in real time by email
    S-8 1 s-8registrationstatement.htm S-8 Document

    As filed with the Securities and Exchange Commission on August 12, 2024
    Registration No. 333-                
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
     
    AirSculpt Technologies, Inc.
    (Exact name of Registrant as specified in its charter)
     
    Delaware 85-1471855
    (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
     
    1111 Lincoln Road, Suite 802
    Miami Beach, Florida 33139
    (Address of principal executive offices) (Zip code)
     
    AirSculpt Technologies, Inc.
    2021 Equity Incentive Plan
    (Full title of the plans)
     
    Dennis Dean
    Interim Chief Executive Officer
    1111 Lincoln Road, Suite 802
    Miami Beach, Florida 33139
    (Name and address of agent for service)
     
    (786) 709-9690
    (Telephone number, including area code, of agent for service)
     
    Copies to:
     
    Thomas P. Conaghan, Esq.
    Richard S. Bass, Esq.
    McDermott Will & Emery LLP
    500 North Capitol Street NW
    Washington, DC 20001-1531
    Telephone: (202) 756-8161
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large accelerated filerAccelerated filer
        
    Non-accelerated filerSmaller reporting company
        
      Emerging growth company




     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  
     
     
     
     
    REGISTRATION OF ADDITIONAL SHARES
    PURSUANT TO GENERAL INSTRUCTION E
     
    Pursuant to General Instruction E of Form S-8, AirSculpt Technologies, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register an aggregate of 4,541,495 additional shares of common stock under the Registrant’s 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to the provisions of the 2021 Plan providing for an automatic annual increase in the number of common stock reserved for issuance under such plan. This Registration Statement hereby incorporates by reference the contents of the Registrant’s previous registration statement on Form S-8 filed with the Commission on October 29, 2021 (Registration No. 333-260609). In accordance with the instructional note of Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement.


    PART II
     
    ITEM 3.
     INCORPORATION OF DOCUMENTS BY REFERENCE
     
    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s annual report on Form 10-K filed with the Commission on February 27, 2024 for the fiscal year ended on December 31, 2023 (the “Annual Report”);
    (b) The Registrant’s quarterly reports on Form 10-Q for the fiscal quarter ended on March 31, 2024, filed with the Commission on May 10, 2024 and for the fiscal quarter ended on June 30, 2024, filed with the Commission on August 9, 2024 and;
    (c) The Registrant’s current reports on Form 8-K filed with the Commission on May 8, 2024 and August 9, 2024;
    (d) The description of the common stock of the Registrant, par value $0.001 per share, contained in Exhibit 4.4 to the Annual Report, including any amendment or report filed with the Commission for the purpose of updating, amending or otherwise modifying such description; and
    (e) The Registrant’s proxy statement on Schedule 14A (to the extent incorporated by reference into the Annual Report) filed with the Commission on March 27, 2024.
     
    All documents, reports and definitive proxy or information statements filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.





    ITEM 8.EXHIBITS
     
    Exhibit
    Number
     Description Incorporated by Reference Filed
    Herewith
     Schedule
    Form
     File
    Number
     Exhibit Filing
    Date
           
    4.1 
    Certificate of Incorporation of the Registrant, as currently in effect
     10-Q 001-40973 3.1 8/11/23  
                 
    4.2 
    By-Laws of the Registrant, as currently in effect
     
     10-Q 001-40973 3.2 12/03/21  
    5.1 
    Opinion of McDermott Will & Emery LLP
             X
           
    23.1 
    Consent of Grant Thornton LLP, independent registered public accounting firm for AirSculpt Technologies, Inc.
             X
           
    23.2 
    Consent of McDermott Will & Emery LLP (included in Exhibit 5.1)
             X
           
    24.1 
    Power of Attorney (included in signature pages of Registration Statement)
             X
           
    99.1 
    AirSculpt Technologies, Inc. 2021 Equity Incentive Plan
     10-Q 001-40973  10.6  12/03/21 
    107
    Filing fee table
             X
     




    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami Beach, Florida, on August 12, 2024.
     
     
    AirSculpt Technologies, Inc.
     
    By:
    /s/ Dennis Dean

    Name:Dennis Dean
    Title:Interim Chief Executive Officer
     


    POWER OF ATTORNEY
     
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dennis Dean as his true and lawful attorney-in-fact and agent, with full power to act alone, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, with full power to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933 this registration statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

    SIGNATURESTITLEDATE
    /s/ Dr. Aaron RollinsExecutive Chairman of the BoardAugust 12, 2024
    Dr. Aaron Rollins
    /s/ Dennis Dean
    Interim Chief Executive Officer
    (Principal Executive Officer)
    August 12, 2024
    Dennis Dean
    /s/ Dennis Dean
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
    August 12, 2024
    Dennis Dean
    /s/ Adam FeinsteinDirectorAugust 12, 2024
    Adam Feinstein
    /s/ Daniel SollofDirectorAugust 12, 2024




    Daniel Sollof
    /s/ Caroline ChuDirectorAugust 12, 2024
    Caroline Chu
    /s/ Thomas AaronDirectorAugust 12, 2024
    Thomas Aaron
    /s/ Kenneth HigginsDirectorAugust 12, 2024
    Kenneth Higgins
    /s/ Pamela NetzkyDirectorAugust 12, 2024
    Pamela Netzky
     





    Exhibit 5.1
     
    mwe.com
     image_0a.jpgimage_1a.jpg
    August 12, 2024
     
    AirSculpt Technologies, Inc.
    1111 Lincoln Road, Suite 802
    Miami Beach, Florida 33139
     
    Re:AirSculpt Technologies, Inc. - Registration Statement on Form S-8
     
    Ladies and Gentleman:
     
    We are rendering this opinion in connection with the Registration Statement on Form S-8 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the registration of 4,541,495 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of AirSculpt Technologies, Inc., a Delaware corporation (the “Company”), pursuant to the AirSculpt Technologies, Inc. 2021 Stock Incentive Plan (the “Plan”).
     
    We have examined: (i) the Registration Statement; (ii) the Company’s Amended and Restated Certificate of Incorporation, as amended and supplemented (the “Amended and Restated Certificate of Incorporation”); (iii) the Company’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”); (iv) the Plan; and (v) the corporate proceedings relating to the registration of the Shares pursuant to the Plan.
     
    In addition to the examination outlined above, we have conferred with various officers of the Company and have ascertained or verified, to our satisfaction, such additional facts as we deemed necessary or appropriate for the purposes of this opinion. In our examination, we have assumed the authenticity of all documents submitted to us as originals, the conformity to the original documents of all documents submitted to us as copies, the genuineness of all signatures on documents reviewed by us and the legal capacity of natural persons.
     
    Based on the foregoing, we are of the opinion that the Shares that constitute original issuance shares will be validly issued, fully paid and nonassessable by the Company when the issuance of such Shares has been duly and validly approved by the Board of Directors of the Company and such Shares have been delivered in accordance with the Plan.
     
    We do not express any opinion herein concerning any law other than the Delaware General Corporation Law, as currently in effect.
     




    We consent to the filing of this opinion as an exhibit to the Registration Statement and we consent to the use of our name wherever it appears in the Registration Statement. In giving this consent, we do not hereby admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.
     
    Very truly yours,
     
    /s/ McDermott Will & Emery LLP
     
    imagea.jpg
     
     




    Exhibit 23.1
     
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
     
    We have issued our report dated February 27, 2024 with respect to the consolidated financial statements of AirSculpt Technologies, Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2023, which are incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement.
     
    /s/ GRANT THORNTON LLP
     
    Tampa, Florida
    August 12, 2024
     



    Get the next $AIRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIRS

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    5/14/2024$8.25 → $5.00Outperform → Market Perform
    Leerink Partners
    11/11/2022$4.00Overweight → Neutral
    Piper Sandler
    6/16/2022$17.00 → $8.50Overweight → Equal-Weight
    Morgan Stanley
    11/23/2021$18.00Outperform
    Raymond James
    11/23/2021$17.00Overweight
    Morgan Stanley
    11/23/2021$26.00Outperform
    SVB Leerink
    11/23/2021$22.00Overweight
    Piper Sandler
    More analyst ratings

    $AIRS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by AirSculpt Technologies Inc.

    SCHEDULE 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    11/14/25 6:07:40 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by AirSculpt Technologies Inc.

    10-Q - Airsculpt Technologies, Inc. (0001870940) (Filer)

    11/7/25 4:37:23 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Airsculpt Technologies, Inc. (0001870940) (Filer)

    11/7/25 6:08:27 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AirSculpt Technologies Appoints Mike Doyle as Non-Executive Chairman of the Board

    MIAMI BEACH, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced the appointment of Mike Doyle as the Non-Executive Chairman of its Board of Directors. Mr. Doyle brings over 30 years of leadership experience in the multi-center healthcare sector. He also serves on several boards where he is recognized for both operating experience and strategic expertise. Yogi Jashnani, CEO of AirSculpt, commented, "Mike has helped to build several successful multi-site healthcare organizations with great experience partnering with surgeons while developing new centers

    11/17/25 5:32:51 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Reports Third Quarter Fiscal 2025 Results

    MIAMI BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the third quarter ended September 30, 2025. Yogi Jashnani, Chief Executive Officer, stated: "During the quarter, we made strong progress on our key initiatives that focused on new growth opportunities, margin improvement, and debt reduction. While third quarter revenue was lower than anticipated, this is reflective of timing, instead of the trajectory of our business. We see a broader market opportunity ahead driven by the structural shift in the aesthetics space due to GLP-1 us

    11/7/25 6:00:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Third Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report third quarter 2025 financial results before market open on Friday, November 7, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13756042 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    10/31/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Jashnani Yogesh covered exercise/tax liability with 24,217 shares, decreasing direct ownership by 5% to 496,759 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    2/5/26 5:45:00 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Arthur Michael J was granted 147,059 shares (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    1/27/26 4:30:15 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Arthur Michael J

    3 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    1/15/26 5:00:10 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AIRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    BTIG Research initiated coverage on AirSculpt Technologies

    BTIG Research initiated coverage of AirSculpt Technologies with a rating of Neutral

    10/17/24 7:13:51 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AirSculpt Technologies from Outperform to Market Perform and set a new price target of $5.00 from $8.25 previously

    5/14/24 7:53:44 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded AirSculpt Technologies from Overweight to Neutral and set a new price target of $4.00

    11/11/22 3:44:11 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Director Feinstein Adam T bought $4,000,000 worth of shares (1,000,000 units at $4.00) (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    6/11/25 5:06:44 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Executive Chairman Rollins Aaron bought $7,629 worth of shares (2,118 units at $3.60), increasing direct ownership by 0.01% to 15,146,039 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    5/20/25 4:11:19 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Jashnani Yogesh bought $18,532 worth of shares (7,000 units at $2.65), increasing direct ownership by 2% to 464,879 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    5/7/25 5:56:15 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Financials

    Live finance-specific insights

    View All

    AirSculpt Technologies Reports Third Quarter Fiscal 2025 Results

    MIAMI BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the third quarter ended September 30, 2025. Yogi Jashnani, Chief Executive Officer, stated: "During the quarter, we made strong progress on our key initiatives that focused on new growth opportunities, margin improvement, and debt reduction. While third quarter revenue was lower than anticipated, this is reflective of timing, instead of the trajectory of our business. We see a broader market opportunity ahead driven by the structural shift in the aesthetics space due to GLP-1 us

    11/7/25 6:00:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Third Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report third quarter 2025 financial results before market open on Friday, November 7, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13756042 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    10/31/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Second Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS), an industry leader and provider of premium body contouring procedures, today announced it will report second quarter 2025 financial results before market open on Friday, August 1, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13754561 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    7/25/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AirSculpt Technologies Inc.

    SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    11/8/24 8:42:05 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by AirSculpt Technologies Inc. (Amendment)

    SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    2/14/24 1:11:48 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by AirSculpt Technologies Inc.

    SC 13G - Airsculpt Technologies, Inc. (0001870940) (Subject)

    4/27/23 9:49:49 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Leadership Updates

    Live Leadership Updates

    View All

    AirSculpt Technologies Names Yogi Jashnani Chief Executive Officer

    MIAMI BEACH, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) ("AirSculpt" or the "Company"), an industry leader and provider of premium body contouring procedures, today announced the appointment of Yogi Jashnani as Chief Executive Officer ("CEO") and a member of the Board of Directors. He succeeds Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer who will continue as Chief Financial Officer, all effective January 7, 2025. A highly-talented, results oriented executive with an accomplished career spanning more than two decades, Mr. Jashnani has architected successful transformations for public and private companies in the aesthetics

    12/17/24 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care